ALS TDI

A $3.2 million grant, awarded through MDA's Augie's Quest research initiative, will help support ALS research at the nonprofit biotech ALS Therapy Development Institute through 2013

Posted on Thursday, April 18, 2013 - 06:00, By: Amy Madsen
MDA and the nonprofit biotech ALS Therapy Development Institute (ALS TDI) have extended their strategic research partnership through 2013. With the extension comes a $3.2 million MDA grant to help support the nonprofit biotech's continued progress toward developing treatments for amyotrophic...

ALS TDI’s phase 2a clinical trial will assess the safety and tolerability of an approved multiple sclerosis drug, Gilenya, in people with amyotrophic lateral sclerosis

Posted on Monday, February 11, 2013 - 06:12, By: Amy Madsen
Update (Aug. 26, 2013): This trial is recruiting participants at its Boston trial site. For updates about the trial’s other sites, see Gilenya in Amyotrophic Lateral Sclerosis, or search for trial ID NCT01786174 at ClinicalTrials.gov. The U.S.

The ALS Therapy Development Institute is hosting a webinar Nov. 15, 2012, about neurodegenerative causes of death, including amyotrophic lateral sclerosis, in retired NFL players

Posted on Monday, November 12, 2012 - 05:00, By: Amy Madsen
A webinar (Web-based seminar) about neurodegenerative causes of death, including amyotrophic lateral sclerosis (ALS), in retired National Football League (NFL) football players is scheduled for 1 p.m. EST, Nov. 15, 2012.

A webinar hosted by ALS TDI reviews the biotech's development of TDI 132 (Gilenya), a drug that modulates the immune system      

Posted on Friday, March 23, 2012 - 12:51, By: Amy Madsen
An overview of the development of TDI 132 for use in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) was the topic of a webinar hosted March 12, 2012, by the nonprofit biotech ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass.

As progress continues in drug discovery and development at the ALS Therapy Development Institute, MDA's Augie's Quest provides $2 million more in support

Posted on Monday, March 5, 2012 - 06:00, By: Amy Madsen
MDA has extended its strategic research partnership with the ALS Therapy Development Institute (ALS TDI) through 2012 and awarded a $2 million grant to support the nonprofit biotech's continued efforts to develop treatments for ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

The MDA-supported ALS Therapy Development Institute plans to launch a phase 2 clinical trial of TDI 132, a compound that modulates the immune system

Posted on Tuesday, February 14, 2012 - 11:30, By: Amy Madsen
A phase 2 clinical trial is set to begin of TDI 132, a compound that modulates the immune system, the ALS Therapy Development Institute (ALS TDI) announced today. TDI 132, also known as fingolimod (brand name Gilenya), already is approved by the U.S. Food and Drug Administration (FDA) for the...

The MDA-supported ALS Therapy Development Institute will collaborate with Biogen Idec and UCB to test CDP7657, a compound that modulates the immune system

Posted on Wednesday, December 21, 2011 - 17:04, By: Margaret Wahl
The ALS Therapy Development Institute (ALS TDI), an MDA-supported, nonprofit biotechnology organization dedicated to developing effective treatments for amyotrophic lateral sclerosis (ALS), will collaborate with two major biotechnology companies to investigate a potential treatment that modulates...

Advertisements

myMuscleTeam